Acorah Software Products - Accounts Production 19.1.200 false true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 11820799 L M Reinders G D Dronkers Mr E Dronkers true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11820799 2024-12-31 11820799 2025-12-31 11820799 2025-01-01 2025-12-31 11820799 frs-core:CurrentFinancialInstruments 2025-12-31 11820799 frs-core:SharePremium 2025-12-31 11820799 frs-core:ShareCapital 2025-12-31 11820799 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 11820799 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 11820799 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 11820799 frs-bus:SmallEntities 2025-01-01 2025-12-31 11820799 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 11820799 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 11820799 frs-bus:OrdinaryShareClass1 2025-01-01 2025-12-31 11820799 frs-bus:OrdinaryShareClass1 2025-12-31 11820799 1 2025-01-01 2025-12-31 11820799 frs-core:UnlistedNon-exchangeTraded 2025-12-31 11820799 frs-core:UnlistedNon-exchangeTraded 2024-12-31 11820799 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-12-31 11820799 frs-core:DisposalsRepaymentsInvestments frs-core:UnlistedNon-exchangeTraded 2025-12-31 11820799 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-12-31 11820799 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 11820799 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-12-31 11820799 frs-bus:Director1 2025-01-01 2025-12-31 11820799 frs-bus:Director2 2025-01-01 2025-12-31 11820799 frs-countries:EnglandWales 2025-01-01 2025-12-31 11820799 2023-12-31 11820799 2024-12-31 11820799 2024-01-01 2024-12-31 11820799 frs-core:CurrentFinancialInstruments 2024-12-31 11820799 frs-core:SharePremium 2024-12-31 11820799 frs-core:ShareCapital 2024-12-31 11820799 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 11820799 frs-bus:OrdinaryShareClass1 2024-01-01 2024-12-31
Registered number: 11820799
Hempflax International Ltd
Unaudited Financial Statements
For The Year Ended 31 December 2025
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 11820799
2025 2024
Notes £ £ £ £
FIXED ASSETS
Investments 4 293,447 7,814,947
293,447 7,814,947
CURRENT ASSETS
Debtors 5 6,832,121 -
Cash at bank and in hand 1,179 994
6,833,300 994
Creditors: Amounts Falling Due Within One Year 6 (2,250 ) (748,896 )
NET CURRENT ASSETS (LIABILITIES) 6,831,050 (747,902 )
TOTAL ASSETS LESS CURRENT LIABILITIES 7,124,497 7,067,045
NET ASSETS 7,124,497 7,067,045
CAPITAL AND RESERVES
Called up share capital 7 359,961 359,961
Share premium account 6,820,257 6,820,257
Profit and Loss Account (55,721 ) (113,173 )
SHAREHOLDERS' FUNDS 7,124,497 7,067,045
Page 1
Page 2
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
L M Reinders
Director
24 April 2026
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Hempflax International Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11820799 . The registered office is C/O London Accountants Hurlingham Studios, Ranelagh Gardens, London, SW6 3PA.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
2.3. Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. 
Current or deferred taxation assets and liabilities are not discounted. 
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. 
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. 
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
2.4. Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.
2.5. Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
Page 3
Page 4
4. Investments
Unlisted
£
Cost or Valuation
As at 1 January 2025 7,814,947
Disposals (7,521,500 )
As at 31 December 2025 293,447
Provision
As at 1 January 2025 -
As at 31 December 2025 -
Net Book Value
As at 31 December 2025 293,447
As at 1 January 2025 7,814,947
5. Debtors
2025 2024
£ £
Due within one year
VAT 330 -
Amounts owed by group undertakings 6,831,791 -
6,832,121 -
During the year, Hempflax International Ltd sold 487 ordinary shares in Hempflax Group B.V. to E. Dronkers B.V. for total consideration of £7,521,500. After sale Hempflax International Ltd holds 19 ordinary shares in Hempflax Group B.V.
E. Dronkers B.V. is a related party by virtue of common control. As at the reporting date, £6,831,791 remained outstanding and is included within debtors. The balance is interest free, and is repayable on demand. The directors consider the balance to be recoverable and no impairment provision has been recognised.
6. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Accruals and deferred income 2,250 -
Amounts owed to group undertakings - 748,896
2,250 748,896
7. Share Capital
2025 2024
Allotted, called up and fully paid £ £
35,996,090 Ordinary Shares of £ 0.01 each 359,961 359,961
8. Ultimate Controlling Party
The company's ultimate controlling party is Mr E Dronkers .
Page 4